More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
April 2024 Ophthalmic News Briefs
Author: Market Scope
Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 antibody positive. Regulators had issued a complete response letter in September 2023, asking Alexion to add meningococcal vaccination and prophylactic administration of antibiotics to the labeling. Ultomiris was already approved for NMOSD in th...
Purchasing one of the following products will open up access to this article's content, which is also available in each comprehensive report/subscription.
This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.